Compare DCBO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | VNDA |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.9M | 474.0M |
| IPO Year | 2020 | 2005 |
| Metric | DCBO | VNDA |
|---|---|---|
| Price | $15.68 | $7.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $32.00 | $14.90 |
| AVG Volume (30 Days) | 101.5K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $12.89 | $21.35 |
| Revenue Next Year | $11.44 | $37.40 |
| P/E Ratio | $22.04 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $14.39 | $3.81 |
| 52 Week High | $33.69 | $9.91 |
| Indicator | DCBO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 47.26 |
| Support Level | N/A | $7.12 |
| Resistance Level | $20.15 | $8.29 |
| Average True Range (ATR) | 0.87 | 0.33 |
| MACD | -0.25 | 0.02 |
| Stochastic Oscillator | 25.73 | 58.20 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.